Exp Clin Endocrinol Diabetes 2010; 118(8): 478-484
DOI: 10.1055/s-0030-1249635
Article

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Insulin Resistance is Associated with Microangiopathy in Type 1 Diabetic Patients Treated with Intensive Insulin Therapy from the Onset of Disease

A. Uruska1 , A. Araszkiewicz1 , D. Zozulinska-Ziolkiewicz1 , P. Uruski2 , B. Wierusz-Wysocka1
  • 1Department of Internal Medicine and Diabetology, Poznan University of Medical Sciences, Raszeja Hospital, Mickiewicza, Poznan, Poland
  • 2Department of Hypertensiology, Angiology and Internal Medicine, Poznan University of Medical Sciences, Dluga, Poznan, Poland
Further Information

Publication History

received 29.12.2009 first decision 15.02.2010

accepted 24.02.2010

Publication Date:
06 April 2010 (online)

Abstract

Aim: The aim of the study was to evaluate the relationship between indirect parameters of insulin resistance (IR) and risk of microangiopathy in patients with type 1 diabetes (DM1), treated from the initial diagnosis with intensive insulin therapy.

Methods: The study group consisted of 81 patients with DM1 (51 men, 30 women), aged 34±6.4, and who were observed for 10±1.5 years. Indirect parameters of IR were evaluated: waist circumference, waist to hip ratio (WHR), body mass index (BMI), daily insulin requirement, gain of weight from the beginning of the disease, lipid profile, estimated glucose disposal rate (eGDR), inflammatory markers and features of metabolic syndrome. Patients were divided into two groups depending on the presence or absence of microangiopathy.

Results: In the group with microangiopathy (n=36) in comparison with patients without complications (n=45) we found: larger waist circumference (88.9±11.7 vs. 83.7±10.2 cm; p=0.036), higher weight before diabetes (77.3±17.0 vs. 67.0±12.5 kg; p=0.008), higher WHR (0.90±0.08 vs. 0.86±0.08; p=0.048), higher level of triglycerides (1.3±0.8 vs. 0.9±0.3 mmol/l; p=0.002) and lower eGDR (7.2±2.4 vs. 8.8±1.9 mg/kg/min; p=0.0019). In patients with microangiopathy, features of metabolic syndrome were found more often (12 (33.3%) vs. 4 (8.9%); p=0.006). A significant relationship, adjusted for sex, age and duration of diabetes, between eGDR and microangiopathy was revealed (OR 0.65 (95%CI 0.49–0.86); p=0.0037).

Conclusion: The results show that in patients with DM1, treated from the initial diagnosis with intensive insulin therapy, there is an independent relationship between IR and the diabetic microangiopathy.

References

  • 1 Alberti KGMM, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group The metabolic syndrome – a new worldwide definition.  Lancet. 2005;  366 1059-10621
  • 2 Araszkiewicz A, Zozulinska-Ziolkiewicz D, Trepinska M. et al . High knowledge about diabetes decreases the likelihood of retinopathy in type 1 diabetic patients treated with intensive insulin therapy from the onset of the disease.  Arch Med Sci. 2005;  1 205-210
  • 3 Araszkiewicz A, Zozulinska-Ziolkiewicz D, Trepinska M. et al . Knowledge after five-day teaching program in intensive insulin therapy performed at the onset of type 1 diabetes influences the development of late diabetic complications.  Diabetes Res Clin Pract.. 2008;  81 61-67
  • 4 Arkkila PE, Koskinen PJ, Kantola IM. et al . Diabetic complications are associated with liver enzyme activities in people with type 1 diabetes.  Diabetes Res Clin Pract. 2001;  52 113-118
  • 5 Brownlee M. The pathobiology of diabetic complications. A unifying mechanism.  Diabetes. 2005;  54 1615-1625
  • 6 Bruno G, Fornengo P, Novelli G. et al . C-reactive protein and 5-year survival in type 2 diabetes: the Casale Monferrato Study.  Diabetes. 2009;  58 926-933
  • 7 Chaturvedi N, Sjoelie AK, Porta M. et al . EURODIAB Prospective Complications Study: Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes.  Diabetes Care. 2001;  24 (2) 284-289
  • 8 DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance.  Am J Physiol. 1979;  237 E214-E223
  • 9 Ekstrand AV, Groop PH, Grönhagen-Riska C. Insulin resistance precedes microalbuminuria in patients with insulin-dependent diabetes mellitus.  Nephrol Dial Transplant. 1998;  13 3079-3083
  • 10 Fernández-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome.  Endocr Rev. 2003;  24 278-301
  • 11 Kilpatrick ES, Rigby AS, Atkin SL. Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: “double diabetes” in the Diabetes Control and Complications Trial.  Diabetes Care. 2007;  30 707-712
  • 12 Koivisto VA, Stevens LK, Mattock M. et al . The EURODIAB IDDM Complications Study Group. Cardiovascular disease and its risk factors in IDDM in Europe.  Diabetes Care. 1996;  19 689-697
  • 13 Krcma M, Cechurova D, Jankovec Z. et al . Effect of mild increase of physical activity on microvasculary reactivity in obese subjects with diabetes mellitus type 2.  Exp Clin Endocrinol Diabetes. 2009;  117 150-152
  • 14 Levey AS, Bosch JP, Lewis JB. et al . A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation Modification of Diet in Renal Disease Study Group.  Ann Intern Med. 1999;  130 461-470
  • 15 Lillioja S, Mott DM, Spraul M. et al . Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus: prospective studies of Pima Indians.  N Engl J Med. 1993;  329 1988-1992
  • 16 McLaughlin T, Abbasi F, Cheal K. et al . Use of metabolic markers to identify overweight individuals who are insulin resistant.  Ann Intern Med. 2003;  139 802-809
  • 17 Müller UA, Femerling M, Reinauer KM. et al . Intensified treatment and education of type 1 diabetes as clinical routine A nationwide quality-circle experience in Germany. ASD (the Working Group on Structured Diabetes Therapy of the German Diabetes Association).  Diabetes Care. 1999;  22 (S 02) B29-B34
  • 18 Nelson RG, Tuttle KR. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease.  Am J Kidney Dis. 2007;  49 S12-S154
  • 19 Orchard TJ, Chang YF, Ferrell RE. et al . Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? Further evidence from the Pittsburgh Epidemiology of Diabetes Complication Study.  Kidney Int. 2002;  62 963-970
  • 20 Orchard TJ, Olson JC, Erbey JR. et al . Insulin resistance-related factors, but not glycaemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study.  Diabetes Care. 2003;  26 1374-1379
  • 21 Perry IJ, Wannamethee SG, Shaper AG. Prospective study of serum gamma-glutamyltransferase and risk of NIDDM.  Diabetes Care. 1998;  21 732-737
  • 22 Penn R, Worthington DJ. Is serum gamma-glutamyltransferase a misleading test?.  Br Med J (Clin Res Ed). 1983;  286 531-535
  • 23 Reaven G. Banting Lecture 1988: Role of insulin resistance in human disease.  Diabetes. 1988;  37 1595-1607
  • 24 Sainaghi PP, Castello L, Bergamasco L. et al . Metabolic characteristics of glucose intolerance: the critical role of obesity.  Exp Clin Endocrinol Diabetes. 2008;  116 86-93
  • 25 Savage DB, Petersen KF, Shulman GI. Mechanisms of insulin resistance in humans and possible links with inflammation.  Hypertension. 2005;  45 828-833
  • 26 Stern SE, Williams K, Ferrannini E. et al . Identification of individuals with insulin resistance using routine clinical measurements.  Diabetes. 2005;  54 333-339
  • 27 The Diabetes Control and Complications Trial Research Group. . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.  N Engl J Med. 1993;  329 977-986
  • 28 Thorn LM, Forsblom C, Fagerudd J. et al . FinnDiane Study Group Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycaemic control (the FinnDiane study).  Diabetes Care. 2005;  28 2019-2024
  • 29 Wannamethee SG, Shaper AG, Lennon L. et al . Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men.  Diabetes Care. 2005;  28 2913-2918
  • 30 Williams KV, Erbey JR, Becker D. et al . Can clinical factors estimate insulin resistance in type 1 diabetes?.  Diabetes. 2000;  49 626-632
  • 31 Yip J, Mattock MB, Morocutti A. et al . Insulin resistance in insulin-dependent diabetic patients with microalbuminuria.  Lancet. 1993;  342 883-887
  • 32 Yki-Järvinen H. Glucose toxicity.  Endocr Rev. 1992;  13 415-431
  • 33 Yki-Järvinen H, Koivisto VA. Continuous subcutaneous insulin infusion therapy decreases insulin resistance in type 1 diabetes.  J Clin. Endocrinol Metab. 1984;  58 659-666
  • 34 Tiikkainen M, Bergholm R, Vehkavaara S. et al . Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content.  Diabetes. 2003;  52 701-707

Correspondence

Dr. A. Uruska

Department of Internal

Medicine and Diabetology

Poznan University of Medical

Sciences, Poland

Raszeja Hospital

Mickiewicza 2

60-834 Poznan

Poland

Phone: (0048) 61 8474579

Fax: (0048) 61 8474579

Email: aleksandrauruska@gmail.com

    >